Atopic dermatitis diagnosis and treatment consensus report

Atopic dermatitis (AD) is a chronic, itchy, and recurrent inflammatory skin disease. AD, which is known as a childhood disease because of its common occurrence, is also an important health problem in adults. With increasing prevalence rates throughout each year, particularly in developed countries, AD has a heterogeneous clinical presentation that varies with age and different degrees of severity. The treatment includes the use of topical or systemic agents after identifying the needs of the patients. Especially, the identification of molecules responsible for pathogenesis recently has allowed the development of tailored treatments. With a better understanding of both the disease and the economic burden of AD recently, studies have gained momentum on diagnosis, treatment, and quality of life. Guidelines and consensus reports addressing diagnostic and therapeutic approaches have been published in our country, too, in parallel to publications in various countries. In this age of rapid information sharing, all kinds of information need to be updated frequently and become further useful. For this purpose, it is planned to develop a current consensus guideline under the leadership of the Dermatoimmunology and Allergy Association, with the contributions of the Cosmetology and the Dermatology Academy Association, Kayseri Dermatology and the Venereal Diseases Association, and Manisa Dermatology and the Venereal Diseases Association, and through the participation of faculty members experienced in the diagnosis and treatment of AD. The topics and the authors were chosen in December 2020. All Medline data published in the years between 1980 and 2021, current AD diagnosis and treatment guidelines, meta-analytical studies, and expert opinions and experiences were reviewed, and section drafts were developed. Literature data and section drafts were assessed and discussed during a meeting held in March 2021 with the participation of all authors. Then, the sections were finalized via e-mail correspondences and submitted as a final consensus report.

Anahtar Kelime:

Atopik dermatit tanı ve tedavi uzlaşı raporu

Öz:

Atopik dermatit (AD) kronik, kaşıntılı ve tekrarlayan enflamatuvar bir deri hastalığıdır. Sık görülmesi nedeni ile çocukluk çağı hastalığı olarak bilinen AD, erişkinlerde de önemli bir sağlık problemi olarak karşımıza çıkmaktadır. Her geçen yıl özellikle gelişmiş ülkelerde görülme sıklığı artan AD, yaşla değişen heterojen bir kliniğe sahiptir ve farklı şiddette seyretmektedir. Tedavi, hastaların ihtiyacı belirlenerek topikal veya sistemik ajanlarla sürdürülür. Özellikle son yıllarda patogenezden sorumlu moleküllerin tanımlanması kişiye özel tedavilerin geliştirilmesine olanak tanımıştır. Son yıllarda AD’nin hem hastalık hem de ekonomik yükünün daha iyi anlaşılması ile tanı, tedavi ve yaşam kalitesine ilişkin çalışmalar hız kazanmıştır. Çeşitli ülkelerde olduğu gibi ülkemizde de tanı ve tedavi yaklaşımları içeren kılavuzlar ve uzlaşı raporları yayınlanmaya başlamıştır. Yaşadığımız hızlı bilgi paylaşımı çağında, tüm bilgilerin sık sık yenilenmesine ve daha yararlı hale getirilmesine ihtiyaç vardır. Bu amaçla, Dermatoimmünoloji ve Alerji Derneği öncülüğünde Kozmetoloji ve Dermatoloji Akademisi Derneği, Kayseri Deri ve Zührevi Hastalıkları Derneği ve Manisa Deri ve Zührevi Hastalıklar Derneği’nin katkıları ve AD tanı ve tedavisinde deneyimli öğretim üyelerinin katılımı ile güncel bir uzlaşı kılavuzu hazırlanması planlanmıştır. Öncelikle Aralık 2020’de konu başlıkları ve yazarlar belirlenmiş ve 1980-2021 yılları arasında yayımlanan tüm Medline verileri, güncel AD tanı ve tedavi kılavuzları, meta-analitik çalışmalar ve uzman görüş ve deneyimleri doğrultusunda bölümler yazılmıştır. Tüm yazarların katılımıyla Mart 2021’de gerçekleştirilen toplantıda literatür verileri ve bölüm taslakları değerlendirilmiş, tartışılmış ve elektronik posta yazışmaları ile son şekli verilerek uzlaşı raporu olarak sunulmuştur

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık

1. Lloyd-Lavery A, Solman L, Grindlay DJC, Rogers NK, Thomas KS, Harman KE: What’s new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors. Clin Exp Dermatol 2019;44:370-5.
2. Hay RJ, Johns NE, Williams HC, et al.: The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527-34.
3. Draaisma E, Garcia-Marcos L, Mallol J, et al.: A multinational study to compare prevalence of atopic dermatitis in the first year of life. Pediatr Allergy Immunol 2015;26:359-66.
4. Broberg A, Svensson A, Borres MP, Berg R: Atopic dermatitis in 5-6-yearold Swedish children: cumulative incidence, point prevalence, and severity scoring. Allergy 2000;55:1025-9.
5. Doğruel D, Bingöl G, Altıntaş DU, et al.: The trend of change of allergic diseases over the years: Three repeated surveys from 1994 to 2014. Int Arch Allergy Immunol 2017;173:178-82.
6. Baççıoğlu A, Söğüt A, Kılıç Ö, Beyhun E: The prevalence of allergic diseases and associated risk factors in school-age children and adults in Erzurum, Turkey. Turk Thorac J 2015;16:68-72.
7. Topal E, Kaplan F, Türker K, Kutlutürk K, Gözükara Baş H: The prevalence of allergic diseases and associated risk factors in the 6-7 age children who are living in Malatya, Turkey. Asthma Allergy Immunol 2017;15:131-6.
8. Cetemen A, Yenigün A: Prevalences of asthma and allergic diseases in primary school children in Aydin. Asthma Allergy Immunol 2012;10:84- 92.
9. Akbaş A, Kılınç F, Yakut Hİ, Metin A: Dermatological disorders in children: A prospective analysis of 4025 patients. Turkish Journal of Pediatric Disease 2015;9:6-11.
10. Civelek E, Sahiner UM, Yüksel H, et al.: Prevalence, burden, and risk factors of atopic eczema in schoolchildren aged 10-11 years: A national multicenter study. J Investig Allergol Clin Immunol 2011;21:270-7.
11. Mortz CG, Andersen KE, Dellgren C, Barington T, Bindslev-Jensen C: Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. Allergy 2015;70:836-45.
12. Liang Y, Chang C, Lu Q: The genetics and epigenetics of atopic dermatitisfilaggrin and other polymorphisms. Clin Rev Allergy Immunol 2016;51:315- 28.
13. Kim BE, Leung DYM: Significance of Skin barrier dysfunction in atopic dermatitis. Allergy Asthma Immunol Res 2018;10:207-15.
14. Liang Y, Tian J, Shen CP, et al.: Therapeutic patient education in children with moderate to severe atopic dermatitis: A multicenter randomized controlled trial in China. Pediatr Dermatol 2018;35:70-5.
15. Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K: The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev 2017;278:246-62.
16. Martino D, Kesper DA, Amarasekera M, Harb H, Renz H, Prescott S: Epigenetics in immune development and in allergic and autoimmune diseases. J Reprod Immunol 2014;104-105:43-8.
17. Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY: Skin barrier abnormalities and immune dysfunction in atopic Dermatitis. Int J Mol Sci 2020;21:2867.
18. Patrick GJ, Archer NK, Miller LS: Which way do we go? Complex interactions in atopic dermatitis pathogenesis. J Invest Dermatol 2021;141:274-84.
19. Nedoszytko B, Reszka E, Gutowska-Owsiak D, et al.: Genetic and epigenetic aspects of atopic dermatitis. Int J Mol Sci 2020;21:6484.
20. Zhu TH, Zhu TR, Tran KA, Sivamani RK, Shi VY: Epithelial barrier dysfunctions in atopic dermatitis: a skin-gut-lung model linking microbiome alteration and immune dysregulation. Br J Dermatol 2018;179:570-81.
21. Kim Y, Lim KM: Skin barrier dysfunction and filaggrin. Arch Pharm Res 2021;44:36-48.
22. Knox S, O’Boyle NM. Skin lipids in health and disease: A review. Chem Phys Lipids 2021;236:105055.
23. Nguyen HLT, Trujillo-Paez JV, Umehara Y, et al.: Role of Antimicrobial peptides in skin barrier repair in individuals with atopic dermatitis. Int J Mol Sci 2020;21:7607.
24. Chieosilapatham P, Kiatsurayanon C, Umehara Y, et al.: Keratinocytes: Innate immune cells in atopic dermatitis. Clin Exp Immunol 2021;204:296- 309.
25. Marschall P, Wei R, Segaud J, et al.: Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis. J Allergy Clin Immunol 2021;147:1778-94.
26. Furue M: Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL17A, IL-22, AHR, and NRF2: Pathogenic implications in atopic dermatitis. Int J Mol Sci 2020;21:5382.
27. DeVore SB, Gonzalez T, Sherenian MG, Herr AB, Khurana Hershey GK: On the surface: Skin microbial exposure contributes to allergic disease. Ann Allergy Asthma Immunol 2020;125:628-38.
28. Harmancı K, Uysal P, Arga M, et al.: Atopik Dermatit Tanı ve Tedavisine Yaklaşım: Ulusal Rehber 2018 ve Ürtiker Güncel Durum Raporu. Asthma Allergy Immunol 2018;16(Suppl 2):1-95.
29. Kapur S, Watson W, Carr S: Atopic dermatitis. Allergy Asthma Clin Immunol 2018;14(Suppl 2):52.
30. Katayama I, Aihara M, Ohya Y, et al.: Japanese guidelines for atopic dermatitis 2017. Allergol Int 2017;66:230-47.
31. Ertam İ, Su Ö, Alper S, et al.: The Turkish guideline for the diagnosis and management of atopic dermatitis-2018. Turkderm-Arch Turk Dermatol Venereology 2018;52:6-23.
32. Diepgen TL, Fartasch M, Hornstein OP: Kriterien zur Beurteilung der atopischen Hautdiathese. Dermatosen 1991;39:79-83.
33. Bannister MJ, Freeman S: Adult-onset atopic dermatitis. Australas J Dermatol 2000;41:225-8.
34. Ozkaya E: Adult-onset atopic dermatitis. J Am Acad Dermatol 2005;52:579- 82.
35. Herzberg J: Little known forms of neurodermitis. Hautarzt 1973;24:47-51.
36. Wüthrich B: Etiology of baker’s eczema. Dermatologica 1970;140:395-6.
37. Horakova E, Wozniak KD: Analysis of the occurrence of morphologic changes in atopic dermatitis in childhood. Z Hautkr 1993;68:155-8.
38. Oranje AP, de Waard-van der Spek FB: Atopic dermatitis: Review 2000 to January 2001. Curr Opin Pediatr 2002;14:410-3.
39. Julián-Gónzalez RE, Orozco-Covarrubias L, Durán-McKinster C, PalaciosLopez C, Ruiz-Maldonado R, Sáez-de-Ocariz M: Less common clinical manifestations of atopic dermatitis: Prevalence by age. Pediatr Dermatol 2012;29:580-3.
40. Engin B, Bülbül Başkan E, Borlu M, et al.: Turkey Atopic Dermatitis Diagnosis and Treatment Guide 2018. Dermatoz 2018;9(Suppl):1-40 (Turkish).
41. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB: Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-95.
42. Silverberg NB: Typical and atypical clinical appearance of atopic dermatitis. Clin Dermatol 2017;35:354-9.
43. Hanifin JM: Adult-onset atopic dermatitis: Fact or fancy? Dermatol Clin 2017;35:299-302.
44. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA: The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol 2017;137:26-30.
45. Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G: Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 2009;160:642-4.
46. Langenbruch A, Zander N, Augustin M: Itch is a Relevant factor of disease burden in patients with atopic dermatitis in German routine care. Presented at the 29th Congress of the EADV 2020; Virtual meeting; October 29-31, 2020.
47. Anuntaseree W, Sangsupawanich P, Osmond C, Mo-Suwan L, Vasiknanonte P, Choprapawon C: Sleep quality in infants with atopic dermatitis: a community-based, birth cohort study. Asian Pac J Allergy Immunol 2012;30:26-31.
48. Chamlin SL, Mattson CL, Frieden IJ, et al.: The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005;159:745-50.
49. Vakharia PP, Chopra R, Sacotte R, et al.: Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 2017;119:548-52.e3.
50. Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD: The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol 2009;26:14-22.
51. Silverberg JI: Public health burden and epidemiology of atopic dermatitis. Dermatol Clin 2017;35:283-9.
52. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM: The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018;78:54-61.e1.
53. Chernyshov PV, Tomas-Aragones L, Manolache L, et al.: Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life. J Eur Acad Dermatol Venereol 2017;31:576-93.
54. Koszorú K, Borza J, Gulácsi L, Sárdy M: Quality of life in patients with atopic dermatitis. Cutis 2019;104:174-7.
55. Beattie PE, Lewis-Jones MS: A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006;155:145-51.
56. Coutanceau C, Stalder JF: Analysis of correlations between patientoriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology 2014;229:248-55.
57. Chrostowska-Plak D, Reich A, Szepietowski JC: Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2013;27:e239-42.
58. Marciniak J, Reich A, Szepietowski JC: Quality of life of parents of children with atopic dermatitis. Acta Derm Venereol 2017;97:711-4.
59. Boguniewicz M, Beck LA, Sher L, et al.: Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract 2021;9:1212-23.e6.
60. Bekić S, Martinek V, Talapko J, Majnaric L, Mihaljevic MV, Skrlec I: Atopic dermatitis and comorbidity. Healthcare (Basel) 2020;8:70.
61. Bantz SK, Zhu Z, Zheng T: The Atopic March: Progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol 2014;5:202.
62. van der Hulst AE, Klip H, Brand PL: Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007;120:565-9.
63. Rivero Gairaud JI: Dermatitis atópica. Rev Méd Costa Rica Centroamerica 2016;LXXIII:711-6.
64. Gilaberte Y, Pérez-Gilaberte JB, Poblador-Plou B, Bliek-Bueno K, GimenoMiguel A, Prados-Torres A: Prevalence and comorbidity of atopic dermatitis in children: A large-scale population study based on real-world data. J Clin Med 2020;9:1632.
65. Ravnborg N, Ambikaibalan D, Agnihotri G, et al.: Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. J Am Acad Dermatol 2021;84:471-8.
66. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al.: Common loss-offunction variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441-6.
67. Rybojad M: La dermatite atopique [Atopic dermatitis]. Archives de pediatrie:organe officiel de la Societe francaise de pediatrie 2012;19:882-5.
68. Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG: The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994;30:35- 9.
69. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindström CB, Svensson Å: Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol 2012;12:11.
70. Gustafsson D, Sjöberg O, Foucard T: Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective followup to 7 years of age. Allergy 2000;55:240-5.
71. Kok WL, Yew YW, Thng TG: Comorbidities associated with severity of atopic dermatitis in young adult males: A national cohort study. Acta Derm Venereol 2019;99:652-6.
72. Lee E, Lee SH, Kwon JW, et al.: Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy 2016;71:692-700.
73. Illi S, von Mutius E, Lau S, et al.: The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004;113:925-31.
74. Silverberg JI: Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol 2017;35:360-6.
75. Rogers AJ, Celedón JC, Lasky-Su JA, Weiss ST, Raby BA: Filaggrin mutations confer susceptibility to atopic dermatitis but not to asthma. J Allergy Clin Immunol 2007;120:1332-7.
76. Kawasaki H, Nagao K, Kubo A, et al.: Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol 2012;129:1538-46.e6.
77. Hong CH, Sussman G, Turchin I, Wiseman M, Gooderham MJ: Approach to the Assessment and management of adult patients with atopic dermatitis: A consensus document. Section III: Evaluation of atopic dermatitis patients for comorbidities. J Cutan Med Surg 2018;22(Suppl 1):17-20.
78. Elias PM, Steinhoff M: “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:1067-70.
79. Brandt EB, Sivaprasad U: Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2:110.
80. Langan SM, Irvine AD, Weidinger S: Atopic dermatitis [published correction appears in Lancet 2020;396:758]. Lancet 2020;396:345-60.
81. Leung DY: Our evolving understanding of the functional role of filaggrin in atopic dermatitis. J Allergy Clin Immunol 2009;124:494-5.
82. Ćosićkić A, Skokić F, Selimović A, et al.: Development of respiratory allergies, asthma and allergic rhinitis in children with atopic dermatitis. Acta Clin Croat 2017;56:308-17.
83. Mariño-Sánchez F, Valls-Mateus M, de Los Santos G, Plaza AM, Cobeta I, Mullol J: Multimorbidities of pediatric allergic rhinitis. Curr Allergy Asthma Rep 2019;19:13.
84. Vaňková R, Čelakovská J, Bukač J, Krčmová I, Krejsek J, Andrýs C: Sensitization to molecular components in 104 atopic dermatitis patients in relation to subgroups of patients suffering from bronchial asthma and allergic rhinitis. Acta Medica (Hradec Kralove) 2020;63:164-75.
85. Gray CL, Levin ME, Du Toit G: Respiratory comorbidity in South African children with atopic dermatitis. S Afr Med J 2017;107:904-9.
86. Paller AS, Spergel JM, Mina-Osorio P, Irvine AD: The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol 2019;143:46-55.
87. Silverberg JI, Gelfand JM, Margolis DJ, et al.: Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol 2018;121:604-12.e3.
88. Oliveira C, Torres T: More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol 2019;29:250-8.
89. Dalgard FJ, Gieler U, Tomas-Aragones L, et al.: The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015;135:984-91.
90. Billeci L, Tonacci A, Tartarisco G, Ruta L, Pioggia G, Gangemi S: Association between atopic dermatitis and autism spectrum disorders: A systematic review. Am J Clin Dermatol 2015;16:371-88.
91. Zuberbier T, Orlow SJ, Paller AS, et al.: Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006;118:226- 32.
92. Egeberg A, Andersen YM, Gislason GH, Skov L, Thyssen JP: Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy 2017;72:783-91.
93. Nicholas MN, Gooderham MJ: Atopic dermatitis, depression, and suicidality. J Cutan Med Surg 2017;21:237-42.
94. Lee S, Shin A: Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry 2017;17:3.
95. Yaghmaie P, Koudelka CW, Simpson EL: Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013;131:428-33.
96. Schmitt J, Romanos M, Schmitt NM, Meurer M, Kirch W: Atopic eczema, and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA 2009;301:724-6.
97. Schmitt J, Buske-Kirschbaum A, Roessner V: Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy 2010;65:1506-24.
98. Strom MA, Fishbein AB, Paller AS, Silverberg JI: Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. Br J Dermatol 2016;175:920-9.
99. Reuveni H, Chapnick G, Tal A, Tarasiuk A: Sleep fragmentation in children with atopic dermatitis. Arch Pediatr Adolesc Med 1999;153:249-53.
100. Yokomaku A, Misao K, Omoto F, et al.: A study of the association between sleep habits and problematic behaviors in preschool children. Chronobiol Int 2008;25:549-64.
101. Hiscock H, Canterford L, Ukoumunne OC, Wake M: Adverse associations of sleep problems in Australian preschoolers: national population study. Pediatrics 2007;119:86-93.
102. Catal F, Topal E, Soylu N, et al.: Psychiatric disorders, and symptoms severity in preschool children with atopic eczema. Allergol Immunopathol (Madr) 2016;44:120-4.
103. Hon KL, Leung TF, Wong KY, Chow CM, Chuh A, Ng PC: Does age or gender influence quality of life in children with atopic dermatitis?. Clin Exp Dermatol 2008;33:705-9.
104. Silverberg JI, Greenland P: Eczema, and cardiovascular risk factors in 2 US adult population studies. J Allergy Clin Immunol 2015;135:721-8.e6.
105. Su VY, Chen TJ, Yeh CM, et al.: Atopic dermatitis, and risk of ischemic stroke: a nationwide population-based study. Ann Med 2014;46:84-9.
106. Drucker AM, Qureshi AA, Dummer TJB, Parker L, Li WQ: Atopic dermatitis and risk of hypertension, type 2 diabetes, myocardial infarction, and stroke in a cross-sectional analysis from the Canadian Partnership for Tomorrow Project. Br J Dermatol 2017;177:1043-51.
107. Standl M, Tesch F, Baurecht H, et al.: Association of atopic dermatitis with cardiovascular risk factors and diseases. J Invest Dermatol 2017;137:1074- 81.
108. Ascott A, Mulick A, Yu AM, et al.: Atopic eczema, and major cardiovascular outcomes: A systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol 2019;143:1821-9.
109. Andersen YMF, Egeberg A, Hamann CR, et al.: Poor agreement in questionnaire-based diagnostic criteria for adult atopic dermatitis s a challenge when examining cardiovascular comorbidity. Allergy 2018;73:923-31.
110. Thyssen JP, Halling-Overgaard AS, Andersen YMF, Gislason G, Skov L, Egeberg A: The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2018;178:1272-9.
111. Strom MA, Silverberg JI: Associations of physical activity and sedentary behaviour with atopic disease in United States children. J Pediatr 2016;174:247-53.e3.
112. Zhang A, Silverberg JI: Association of atopic dermatitis with being overweight and obese: a systematic review and meta-analysis. J Am Acad Dermatol 2015;72:606-16.e4.
113. Narla S, Silverberg JI: Association between atopic dermatitis and autoimmune disorders in US adults and children: A cross-sectional study. J Am Acad Dermatol 2019;80:382-9.
114. Kappelman MD, Galanko JA, Porter CQ, Sandler RS: Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011;96:1042-6.
115. Sastre J, Baldrich ES, Armario Hita JC, et al.: Consensus on the clinical approach to moderate-to-severe atopic dermatitis in Spain: A Delphi survey. Dermatol Res Pract 2020;2020:1524293.
116. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C: Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. J Am Acad Dermatol 2015;72:992-1002.
117. Cheng J, Zens MS, Duell E, Perry AE, Chapman MS, Karagas MR: History of allergy and atopic dermatitis in relation to squamous cell and Basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2015;24:749- 54.
118. Ruff S, Egeberg A, Andersen YMF, Gislason G, Skov L, Thyssen JP: Prevalence of cancer in adult patients with atopic dermatitis: A Nationwide study. Acta Derm Venereol 2017;97:1127-9.
119. Hagströmer L, Ye W, Nyrén O, Emtestam L: Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005;141:1123-7.
120. Wang L, Bierbrier R, Drucker AM, Chan AW: Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: A systematic review and meta-analysis. JAMA Dermatol 2020;156:158-71.
121. Chou WY, Lai PY, Hu JM, et al.: Association between atopic dermatitis and colorectal cancer risk: A nationwide cohort study. Medicine (Baltimore) 2020;99:e18530.
122. Haeck IM, Hamdy NA, Timmer-de Mik L, et al.: Low bone mineral density in adult patients with moderate to severe atopic dermatitis. Br J Dermatol 2009;161:1248-54.
123. Baïz N, Dargent-Molina P, Wark JD, et al.: EDEN Mother-Child Cohort Study Group. Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis. J Allergy Clin Immunol 2014;133:147-53.
124. van Velsen SG, Knol MJ, van Eijk RL, et al.: Bone mineral density in children with moderate to severe atopic dermatitis. J Am Acad Dermatol 2010;63:824-31.
125. Wu D, Wu XD, Zhou X, et al.: Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta-analysis. Ann Transl Med 2021;9:40.
126. Wollenberg A, Barbarot S, Bieber T, et al.: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I [published correction appears in J Eur Acad Dermatol Venereol 2019 Jul;33(7):1436]. J Eur Acad Dermatol Venereol 2018;32:657-82.
127. Damiani G, Calzavara-Pinton P, Stingeni L, et al.: Italian guidelines for therapy of atopic dermatitis-adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatol Ther 2019;32:e13121.
128. Smith S, Baker C, Gebauer K, et al.: Atopic dermatitis in adults: An Australian management consensus. Australas J Dermatol 2020;61:23-32.
129. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;92(Suppl):44-7.
130. Weidinger S, Novak N: Atopic dermatitis. Lancet 2016;387:1109-22.
131. Kavlak Bozkurt P, Özkaya P: Atopic dermatitis diagnostic criteria with beneficial and controversial aspects: review. Türkiye Klinikleri J Dermatol 2012;22:141-8.
132. Williams HC, Burney PG, Pembroke AC, Hay RJ: The U.K. Working Party’s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol 1994;131:406-16.
133. Yazganoglu KD, Ozkaya E: Non-typical morphology and localization in Turkish atopic dermatitis patients with onset before the age of 18 years. Indian J Dermatol Venereol Leprol 2011;77:23-7.
134. Kulthanan K, Samutrapong P, Jiamton S, Tuchinda P: Adult-onset atopic dermatitis: A cross-sectional study of natural history and clinical manifestation. Asian Pac J Allergy Immunol 2007;25:207-14.
135. Eichenfield LF, Tom WL, Chamlin SL, et al.: Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014;70:338-51.
136. Thijs JL, de Bruin-Weller MS, Hijnen D: Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin North Am 2017;37:51-61.
137. Kartal D, Koç Babayiğit F: Atopik dermatit tanısında in vivo ve in vitro testler. Ed. Su Küçük Ö. Atopik Dermatit 1. Baskı. Ankara: Türkiye Klinikleri; 2020. P17-21.
138. Wallach D, Taïeb A: Atopic dermatitis/atopic eczema. Chem Immunol Allergy 2014;100:81-96.
139. Taşkapan O: The Significance of skin tests in atopic dermatitis. Turk J Dermatol 2013;7,236-41.
140. Kim JS: Pediatric atopic dermatitis: the importance of food allergens. Semin Cutan Med Surg 2008;27:156-60.
141. Akdis CA, Akdis M, Bieber T, et al.: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma, and Immunology/PRACTALL. J Allergy Clin Immunol 2006;118:152-69.
142. Boyce JA, Assa’ad A, Burks AW, et al.: Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAIDSponsored Expert Panel Report. J Allergy Clin Immunol 2010;126:1105-18.
143. Eichenfield LF: Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004;59(Suppl 78):86-92.
144. Schmitt J, Langan S, Williams HC; European Dermato-Epidemiology Network: What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:1389-98.
145. Stalder JF, Barbarot S, Wollenberg A, et al.: Patient-Oriented SCORAD (POSCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011;66:1114-21.
146. Housman TS, Patel MJ, Camacho F, Feldman SR, Fleischer AB Jr, Balkrishnan R: Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol 2002;147:1192-8.
147. Lob-Corzilius T, Böer S, Scheewe S, et al.: The ‘skin detective questionnaire’: a survey tool for self-assessment of patients with atopic dermatitis. first results of its application. Dermatol Psychosom 2004;5:141-6.
148. Charman CR, Venn AJ, Williams HC: The patient-oriented eczema measure: Development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol 2004;140:1513-9.
149. Carel K, Bratton DL, Miyazawa N, et al.: The Atopic Dermatitis Quickscore (ADQ): validation of a new parent-administered atopic dermatitis scoring tool. Ann Allergy Asthma Immunol 2008;101:500-7.
150. Chren MM: The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin 2012;30:231-6, xiii.
151. Pariser DM, Simpson EL, Gadkari A, et al.: Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020;36:367-76.
152. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
153. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB: Practical issues on interpretation of scoring atopic dermatitis: The SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-8.
154. Vourc’h-Jourdain M, Barbarot S, Taieb A, et al.: Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology 2009;218:246-51.
155. Hanifin JM, Thurston M, Omoto M, et al.: The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11-8.
156. Tremp M, Knafla I, Burg G, Wüthrich B, Schmid-Grendelmeier P: “EASIdig”--a digital tool to document disease activity in atopic dermatitis. Dermatology 2011;223:68-73.
157. Charman C, Williams H: Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000;136:763-9.
158. Siegfried E, Korman N, Molina C, Kianifard F, Abrams K: Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis [published correction appears in J Dermatolog Treat 2006;17:256]. J Dermatolog Treat 2006;17:143-50.
159. Rehal B, Armstrong AW: Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011;6:e17520.
160. Perez-Chada L, Taliercio VL, Gottlieb A, et al.: Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. J Am Acad Dermatol 2019:S0190-9622:32745-8.
161. Simpson E, Eckert L, Gadkari A, et al.: Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol 2019;19:15.
162. Kahyaoğlu Süt H, Unsar S: Is EQ-5D a valid quality of life instrument in patients with acute coronary syndrome? Anadolu Kardiyol Derg 2011;11:156-62.
163. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
164. Oztürkcan S, Ermertcan AT, Eser E, Sahin MT: Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol 2006;45:1300-7.
165. Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM: Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002;204:43-9.
166. Aksu AE, Urer MS, Sabuncu I, Saracoglu ZN, Chren MM: Turkish version of Skindex-29. Int J Dermatol 2007;46:350-5.
167. Lewis-Jones MS, Finlay AY: The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995;132:942-9.
168. Holme SA, Man I, Sharpe JL, Dykes PJ, Lewis-Jones MS, Finlay AY: The Children’s Dermatology Life Quality Index: Validation of the cartoon version. Br J Dermatol 2003;148:285-90.
169. Wollenberg A, Barbarot S, Bieber T, et al.: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018;32:850-78.
170. Siegfried EC, Hebert AA: Diagnosis of atopic dermatitis: Mimics, overlaps, and complications. J Clin Med 2015;4:884-917.
171. Turner JD, Schwartz RA: Atopic dermatitis. A clinical challenge. Acta Dermatovenerol Alp Pannonica Adriat 2006;15:59-68.
172. Heratizadeh A, Werfel T, Wollenberg A, et al.: Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol 2017;140:845-53.
173. Zhao M, Liang Y, Shen C, Wang Y, Ma L, Ma X: Patient education programs in pediatric atopic dermatitis: a systematic review of randomized controlled trials and meta-analysis. Dermatol Ther (Heidelb) 2020;10:449-64.
174. Galli E, Neri I, Ricci G, et al.: Consensus conference on clinical management of pediatric atopic dermatitis. Ital J Pediatr 2016;42:26.
175. Kantor R, Silverberg JI: Environmental risk factors and their role in the management of atopic dermatitis. Expert Rev Clin Immunol 2017;13:15- 26.
176. Bonamonte D, Filoni A, Vestita M, et al.: The role of the environmental risk factors in the pathogenesis and clinical outcome of atopic dermatitis. Biomed Res Int 2019;2019:2450605.
177. Geoghegan JA, Irvine AD, Foster TJ: Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol 2018;26:484-97.
178. Lin TK, Zhong L, Santiago JL: Association between stress and the HPA axis in the atopic dermatitis. Int J Mol Sci 2017;18:2131.
179. Caubet JC, Eigenmann PA: Allergic triggers in atopic dermatitis. Immunol Allergy Clin North Am 2010;30:289-307.
180. Borlu M, Öksüm Solak E: Diagnosis and management in adult onset atopic dermatitis. Ed. Su Küçük Ö. Atopik Dermatit 1. Baskı. Ankara: Türkiye Klinikleri: 2020.p71-4.
181. Healy E, Bentley A, Fidler C, Chambers C: Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011;16:387-95.
182. Ng JP, Liew HM, Ang SB: Use of emollients in atopic dermatitis. J Eur Acad Dermatol Venereol 2015;29:854-7.
183. Darsow U, Wollenberg A, Simon D, et al.: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-28.
184. Grimalt R, Mengeaud V, Cambazard F: Study investigators’ group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: A randomized controlled study. Dermatology 2007;214:61-7.
185. Berth-Jones J, Damstra RJ, Golsch S, et al.: Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367.
186. Lucky AW, Leach AD, Laskarzewski P, Wenck H: Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997;14:321-4.
187. Eichenfield LF, Tom WL, Berger TG, et al.: Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014;71:116-32.
188. Odyakmaz Demirsoy E. Atopik dermatitte topikal tedavi. Ed. Su Küçük Ö. Atopik Dermatit 1. Baskı. Ankara: Türkiye Klinikleri: 2020.p.38-43.
189. Miller DW, Koch SB, Yentzer BA, et al.: An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011;10:531-7.
190. Nowicki R, Trzeciak M, Wilkowska A, et al.: Atopic dermatitis: current treatment guidelines. Statement of the experts of the dermatological section, polish society of allergology, and the allergology section, polish society of dermatology. Postepy Dermatol Alergol 2015;32:239-49.
191. Voegeli D: The effect of washing and drying practices on skin barrier function. J Wound Ostomy Continence Nurs 2008;35:84-90.
192. Simpson EL: Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin 2010;26:633-40.
193. Barnes PJ: Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:451-68.
194. Aubert-Wastiaux H, Moret L, Le Rhun A, et al.: Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins, and frequency. Br J Dermatol 2011;165:808-14.
195. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-6.
196. Williams HC: Established corticosteroid creams should be applied only once daily in patients with atopic eczema. BMJ 2007;334:1272.
197. Drake LA, Dinehart SM, Farmer ER, et al.: Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology. J Am Acad Dermatol 1996;35:615-9.
198. Mayba JN, Gooderham MJ: Review of atopic dermatitis and topical therapies. J Cutan Med Surg 2017;21:227-36.
199. Lebwohl MG, Del Rosso JQ, Abramovits W, et al.: Pathways to managing atopic dermatitis: consensus from the experts. J Clin Aesthet Dermatol 2013;6(7 Suppl):S2-18.
200. Chia BK, Tey HL: Systematic review on the efficacy, safety, and costeffectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 2015;26:122-32.
201. Tennis P, Gelfand JM, Rothman KJ: Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011;165:465-73.
202. Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS: Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 2016;8:853-66.
203. Freund YR, Akama T, Alley MR, et al.: Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 2012;586:3410-4.
204. Jarnagin K, Chanda S, Coronado D, et al.: Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol 2016;15:390-6.
205. Zane LT, Kircik L, Call R, et al.: Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximaluse systemic exposure Study. Pediatr Dermatol 2016;33:380-7.
206. Murrell DF, Gebauer K, Spelman L, Zane LT: Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proofof-concept study. J Drugs Dermatol 2015;14:1108-12.
207. Nygaard U, Deleuran M, Vestergaard C: Emerging treatment options in atopic dermatitis: topical therapies. Dermatology 2017;233:333-43.
208. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC: Interventions to reduce staphylococcus aureus in the management of atopic eczema: an updated cochrane review. Br J Dermatol 2010;163:12-26.
209. Tollefson MM, Bruckner AL: Section on dermatology. Atopic dermatitis: skin-directed management. Pediatrics 2014;134:e1735-44.
210. Ong PY: Recurrent MRSA skin infections in atopic dermatitis. J Allergy Clin Immunol Pract 2014;2:396-9.
211. Drake LA, Fallon JD, Sober A: Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994;31:613-6.
212. Berberian BJ, Breneman DL, Drake LA, et al.: The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol 1999;38:145-8.
213. Horio T: Allergic and photoallergic dermatitis from diphenhydramine. Arch Dermatol 1976;112:1124-6.
214. Food and Drug Administration, HHS: Labeling of diphenhydraminecontaining drug products for over-the-counter human use. Final rule. Fed Regist 2002;67:72555-9.
215. Gooderham M: Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett 2013;18:1-4.
216. Fridman JS, Scherle PA, Collins R, et al.: Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol 2011;131:1838-44.
217. Fukuyama T, Ehling S, Cook E, Bäumer W: Topically administered januskinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther 2015;354:394-405.
218. Bissonnette R, Poulin Y, Zhou Y, et al.: Efficacy and safety of topical WBI1001 in patients with mild to severe atopic dermatitis: results from a 12- week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol 2012;16:853-60.
219. Bogaczewicz J, Malinowska K, Sysa-Jedrzejowska A, Wozniacka A: Medium dose ultraviolet A1 phototherapy and mRNA expression of interleukin 8, interferon γ, and chemokine receptor 4 in acute skin lesions in atopic dermatitis. Postepy Dermatol Alergol 2016;33:170-5.
220. Gambichler T, Kreuter A, Tomi NS, Othlinghaus N, Altmeyer P, Skrygan M: Gene expression of cytokines in atopic eczema before and after ultraviolet A1 phototherapy. Br J Dermatol 2008;158:1117-20.
221. El Samahy MH, Attia EA, Saad AA, Mahmoud EY: Circulating CD4(+) CD25(high) FoxP3(+) T-regulatory cells in patients with atopic dermatitis after narrowband-ultraviolet B phototherapy. Int J Dermatol 2015;54:e424- 9.
222. Yoshimura-Mishima M, Akamatsu H, Namura S, Horio T: Suppressive effect of ultraviolet (UVB and PUVA) radiation on superantigen production by Staphylococcus aureus. J Dermatol Sci 1999;19:31-6.
223. Staniek V, Liebich C, Vocks E, et al.: Modulation of cutaneous SP receptors in atopic dermatitis after UVA irradiation. Acta Derm Venereol 1998;78:92- 4.
224. Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K: Psoralenultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009;55:40-6.
225. Jekler J, Larkö O: UVB phototherapy of atopic dermatitis. Br J Dermatol 1988;119:697-705.
226. Jekler J, Larkö O: UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol 1991;125:569-72.
227. Granlund H, Erkko P, Remitz A, et al.: Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001;81:22-7.
228. Yoshiike T, Aikawa Y, Sindhvananda J, Ogawa H: A proposed guideline for psoralen photochemotherapy (PUVA) with atopic dermatitis: successful therapeutic effect on severe and intractable cases. J Dermatol Sci 1993;5:50-3.
229. de Kort WJ, van Weelden H: Bath psoralen-ultraviolet a therapy in atopic eczema. J Eur Acad Dermatol Venereol 2000;14:172-4.
230. Der-Petrossian M, Seeber A, Hönigsmann H, Tanew A: Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol 2000;142:39-43.
231. Tzaneva S, Kittler H, Holzer G, et al.: 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010;162:655-60.
232. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schöpf E: High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26:225-30.
233. Kowalzick L, Kleinheinz A, Weichenthal M, et al.: Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol 1995;75:43-5.
234. Abeck D, Schmidt T, Fesq H, et al.: Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000;42:254-7.
235. Seçkin D, Fototerapi Çalışma Grubu, Yılmaz E: Results of Photo(chemo) therapy applications survey in TurkeyTURKDERM-Arch Turkish Dermatology Venerol 2010;44:131-7.
236. George SA, Bilsland DJ, Johnson BE, Ferguson J: Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 1993;128:49-56.
237. Reynolds NJ, Franklin V, Gray JC, et al.: Narrow-band ultraviolet B and broadband ultraviolet a phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:2012-6.
238. Clayton TH, Clark SM, Turner D, Goulden V: The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007;32:28-33.
239. Clowry J, Molloy K, Nestor L, et al.: Narrow-band ultraviolet B phototherapy outcomes in atopic dermatitis-A single-centre retrospective review. Photodermatol Photoimmunol Photomed 2018;34:217-9.
240. Darné S, Leech SN, Taylor AE: Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. Br J Dermatol 2014;170:150-6.
241. Sidbury R, Davis DM, Cohen DE, et al.: Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014;71:327-49.
242. Heinlin J, Schiffner-Rohe J, Schiffner R, et al.: A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis. J Eur Acad Dermatol Venereol 2011;25:765-73.
243. Nisticò SP, Saraceno R, Capriotti E, Felice CD, Chimenti S: Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. Photomed Laser Surg 2008;26:14-8.
244. Farahnik B, Beroukhim K, Danesh M, et al.: Successful use of a modified goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study. J Am Acad Dermatol 2016;75:1068-71.
245. Wolf P, Georgas D, Tomi NS, Schempp CM, Hoffmann K: Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. Photochem Photobiol Sci 2013;12:174-81.
246. Rubegni P, Poggiali S, Cevenini G, et al.: Long term follow-up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. J Eur Acad Dermatol Venereol 2013;27:523-6.
247. Cameron H, Yule S, Dawe RS, Ibbotson SH, Moseley H, Ferguson J: Review of an established UK home phototherapy service 1998-2011: improving access to a cost-effective treatment for chronic skin disease. Public Health 2014;128:317-24.
248. He A, Feldman SR, Fleischer AB Jr: An assessment of the use of antihistamines in the management of atopic dermatitis. J Am Acad Dermatol 2018;79:92-6.
249. Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ: Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019;1:CD012167.
250. Schmitt J, Buske-Kirschbaum A, Tesch F, et al.: Increased attention-deficit/ hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy 2018;73:615-26.
251. Diepgen TL; Early Treatment of the Atopic Child Study Group: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002;13:278-86.
252. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S: Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003;148:1212-21.
253. Yamanaka K, Motomura E, Noro Y, et al.: Olopatadine, a non-sedating H1 antihistamine, decreases the nocturnal scratching without affecting sleep quality in atopic dermatitis. Exp Dermatol 2015;24:227-9.
254. Werfel T, Layton G, Yeadon M, et al.: Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol 2019;143:1830-17.e4.
255. Wollenberg A, Christen-Zäch S, Taieb A, et al.: ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020;34:2717-44.
256. Ring J, Alomar A, Bieber T, et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-60.
257. Drucker AM, Eyerich K, de Bruin-Weller MS, et al.: Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018;178:768-75.
258. Wollenberg A, Oranje A, Deleuran M, et al.: ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016;30:729-47.
259. Schmitt J, Schmitt N, Meurer M: Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606-19.
260. Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J: Oral cyclosporine weekend therapy: a new maintenance therapeutic option in patients with severe atopic dermatitis. Pediatr Dermatol 2015;32:551-2.
261. Schmitt J, Schäkel K, Fölster-Holst R, et al.: Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebocontrolled multicentre trial. Br J Dermatol 2010;162:661-8.
262. Gooderham M, Lynde CW, Papp K, et al.: Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2017;21:31-9.
263. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J: Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J Allergy Clin Immunol 2014;133:429-38.
264. Thijs JL, Van Der Geest BAM, Van Der Schaft J, et al.: Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J Dermatolog Treat 2017;28:242-5.
265. Phan K, Smith SD: Mycophenolate mofetil and atopic dermatitis: Systematic review and meta-analysis. J Dermatolog Treat 2020;31:810-4.
266. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA: Enteric-coated mycophenolate sodium versus cyclosporin a as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074-84.
267. Heller M, Shin HT, Orlow SJ, Schaffer JV: Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007;157:127-32.
268. Waxweiler WT, Agans R, Morrell DS: Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol 2011;28:689-94.
269. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI: A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011;128:353-9.
270. Berth-Jones J, Takwale A, Tan E, et al.: Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:324-30.
271. Meggitt SJ, Gray JC, Reynolds NJ: Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a doubleblind, randomised controlled trial. Lancet 2006;367:839-46.
272. Caufield M, Tom WL: Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol 2013;68:29-35.
273. Hon KL, Ching GK, Leung TF, Chow CM, Lee KK, Ng PC: Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009;20:141-5.
274. Fuggle NR, Bragoli W, Mahto A, Glover M, Martinez AE, Kinsler VA: The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol 2015;72:108- 14.
275. Flohr C, Irvine AD: Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013;132:774-e6.
276. Dvorakova V, O’Regan GM, Irvine AD: Methotrexate for Severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol 2017;34:528-34.
277. Gerbens LAA, Hamann SAS, Brouwer MWD, Roekevisch E, Leeflang MMG, Spuls PI: Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol 2018;178:1288-96.
278. Goujon C, Viguier M, Staumont-Sallé D, et al.: Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase iii randomized noninferiority Trial. J Allergy Clin Immunol Pract 2018;6:562- 9.e3.
279. Vestergaard C, Wollenberg A, Barbarot S, et al.: European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy, and lactation period. J Eur Acad Dermatol Venereol 2019;33:1644-59.
280. Ruzicka T, Lynde CW, Jemec GB, et al.: Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebocontrolled, multicentre trial. Br J Dermatol 2008;158:808-17.
281. Grahovac M, Molin S, Prinz JC, Ruzicka T, Wollenberg A: Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 2010;162:217-8.
282. Samrao A, Berry TM, Goreshi R, Simpson EL: A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012;148:890-7.
283. Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW: Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 2011;3:89-95.
284. Paul C, Lahfa M, Bachelez H, Chevret S, Dubertret L: A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002;147:518-22.
285. Bemanian MH, Movahedi M, Farhoudi A, et al.: High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran J Allergy Asthma Immunol 2005;4:139-43.
286. Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D: Immunoadsorption in dermatology. Ther Apher Dial 2012;16:311-20.
287. Kasperkiewicz M, Mook SC, Knuth-Rehr D, et al.: IgE-selective immunoadsorption for severe atopic dermatitis. Front Med (Lausanne) 2018;5:27.
288. Hanifin JM, Schneider LC, Leung DY, et al.: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-97.
289. Jang IG, Yang JK, Lee HJ, et al.: Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000;42:1033-40.
290. Reinhold U, Kukel S, Brzoska J, Kreysel HW: Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993;29:58- 63.
291. Panahi Y, Davoudi SM, Madanchi N, Abolhasani E: Recombinant human interferon gamma (gamma immunex) in treatment of atopic dermatitis. Clin Exp Med 2012;12:241-5.
292. Noh G, Lee KY: Successful interferon alpha therapy in atopic dermatitis of Besnier’s prurigo pattern with normal serum IgE and blood eosinophil fraction: randomized case-controlled study. Cytokine 2001;13:124-8.
293. Beck LA, Thaçi D, Hamilton JD, et al.: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-9.
294. Worm M, Simpson EL, Thaçi D, et al.: Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020;156:131-43.
295. Siegels D, Heratizadeh A, Abraham S, et al.: Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy 2021;76:1053-76.
296. Beck LA, Thaçi D, Deleuran M, et al.: Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2020;21:567-77.
297. Wollenberg A, Beck LA, Blauvelt A, et al.: Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020;182:1120-35.
298. Simpson EL, Paller AS, Siegfried EC, et al.: Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020;156:44-56.
299. Paller AS, Siegfried EC, Thaçi D, et al.: Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebocontrolled phase 3 trial. J Am Acad Dermatol 2020;83:1282-93.
300. Silverberg JI, Yosipovitch G, Simpson EL, et al.: Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol 2020;82:1328-36.
301. de Wijs LEM, Bosma AL, Erler NS, et al.: Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol 2020;182:418-26.
302. Pistone G, Tilotta G, Gurreri R, Castelli E, Curiale S, Bongiorno MR: Ocular surface disease during dupilumab treatment in patients with atopic dermatitis, is it possible to prevent it?. J Eur Acad Dermatol Venereol 2020;34:e255-6.
303. de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ: Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol 2020;183:745-9.
304. Jang DH, Lee JI, Bae JY, Jung HJ, Park MY, Ahn J: Facial erythema after the treatment of dupilumab in SLE patient. Allergy Asthma Clin Immunol 2020;16:60.
305. Chan TC, Wu NL, Wong LS, et al.: Taiwanese dermatological association consensus for the management of atopic dermatitis: A 2020 update. J Formos Med Assoc 2021;120:429-42.
306. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA: Are biologics efficacious in atopic dermatitis? A systematic review and metaanalysis. Am J Clin Dermatol 2018;19:145-65.
307. Ruzicka T, Hanifin JM, Furue M, et al.: Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017;376:826-35.
308. Belloni B, Ziai M, Lim A, et al.: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-5.
309. Wang HH, Li YC, Huang YC: Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol 2016;138:1719-22.e1.
310. Amrol D: Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J 2010;103:554-8.
311. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK: Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013;38:496- 500.
312. Simpson EL, Flohr C, Eichenfield LF, et al.: Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 2018;78:863-71.e11.
313. Baverel P, She D, Piper E, et al.: A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metab Pharmacokinet 2018;33:150-8.
314. Hajar T, Gontijo JRV, Hanifin JM: New and developing therapies for atopic dermatitis. An Bras Dermatol 2018;93:104-7.
315. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122- 8.
316. McDonald BS, Jones J, Rustin M: Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol 2016;41:45-7.
317. Pan Y, Xu L, Qiao J, Fang H: A systematic review of ustekinumab in the treatment of atopic dermatitis. J Dermatolog Treat 2018;29:539-41.
318. Katoh N: Emerging treatments for atopic dermatitis. J Dermatol 2021;48:152-7.
319. Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N: Phase 1 studies to assess the safety, tolerability, and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol 2018;45:701-9.
320. Levy LL, Urban J, King BA: Treatment of recalcitrant atopic dermatitis with the oral janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395-9.
321. Guttman-Yassky E, Silverberg JI, Nemoto O, et al.: Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019;80:913-21.e9.
322. Simpson EL, Lacour JP, Spelman L, et al.: Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020;183:242-55.
323. Rreich k, kabashima k, peris k, et al.: Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020;156:1333-43.
324. Simpson EL, Sinclair R, Forman S, et al.: Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2020;396:255-66.
325. Oldhoff JM, Darsow U, Werfel T, et al.: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-6.
326. Oldhoff JM, Darsow U, Werfel T, et al.: No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006;141:290-4.
327. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:522-6.
328. Nakamura M, Lee K, Singh R, et al.: Eczema as an adverse effect of antiTNFα therapy in psoriasis and other Th1-mediated diseases: a review. J Dermatolog Treat 2017;28:237-41.
329. Katoh N, Ohya Y, Ikeda M, et al.: Japanese guidelines for atopic dermatitis 2020. Allergol Int 2020;69:356-69.
330. Panduru M, Panduru NM, Sălăvăstru CM, Tiplica GS: Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015;29:232-42.
331. Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY: Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2014;113:217-26.
332. Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, García-Romero MT: Synbiotics for prevention and treatment of atopic dermatitis: a metaanalysis of randomized clinical trialsJAMA Pediatr 2016;170:236-42.
333. Huang R, Ning H, Shen M, Li J, Zhang J, Chen X: Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol 2017;7:392.
334. Zhao M, Shen C, Ma L: Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis. Int J Dermatol 2018;57:635-41.
335. Heilskov S, Deleuran MS, Vestergaard C: Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. Dermatol Ther (Heidelb) 2020;10:1215-28.
336. Rodrigues MA, Nogueira M, Torres T: Dupilumab for atopic dermatitis: evidence to date. G Ital Dermatol Venereol 2019;154:696-713.
337. Dupixent (dupilumab) product information. https://www.ema.europa.eu/ en/documents/product-information/dupixent-epar-product-information_ en.pdf. (date of access: 19.04.2021).
338. Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C: New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther 2021;34:e14475.
339. Kage P, Simon JC, Treudler R: A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. J Eur Acad Dermatol Venereol 2020;34:e256-7.
340. Tanei R: Atopic dermatitis in older adults: a review of treatment options. Drugs Aging 2020;37:149-60.
341. Fowler E, Rosen J, Lev-Tov H, Yosipovitch G: Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol 2019;99:899-900.
342. Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M: Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018;41:489-509.
343. Gnarra M, De Simone C, Garcovich M, Garcovich S: Low-dose cyclosporine a in the treatment of severe atopic dermatitis complicated by chronic hepatitis C virus infection. Pediatr Dermatol 2017;34:374-6.
344. Yim RM, Singh I, Armstrong AW: Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. Dermatol Online J 2020;26:13030/qt0j5150df.
345. Ricardo JW, Lipner SR: Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther 2020;3:e13687.
346. Ordóñez-Rubiano MF, Campo I, Casas M: Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients. Dermatol Ther 2020;33:e14172.
347. Kearns DG, Uppal S, Chat VS, Wu JJ: Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. J Am Acad Dermatol 2020;83:e251-2.
348. Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S: Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol 2020;34:e303-4.

APA	atakan n, Yalcin B, ÖZKAYA E, Su O, ÖZTÜRKCAN S, SALMAN A, borlu m, senturk n, KARAKAŞ A, Serdaroğlu S (2022). Atopic dermatitis diagnosis and treatment consensus report. , 86 - 121. 10.4274/turkderm.galenos.2022.73368
Chicago	atakan nilgün,Yalcin Basak,ÖZKAYA Esen,Su Ozlem,ÖZTÜRKCAN Serap,SALMAN Andaç,borlu murat,senturk nilgun,KARAKAŞ Ayşe AKMAN,Serdaroğlu Server Atopic dermatitis diagnosis and treatment consensus report. (2022): 86 - 121. 10.4274/turkderm.galenos.2022.73368
MLA	atakan nilgün,Yalcin Basak,ÖZKAYA Esen,Su Ozlem,ÖZTÜRKCAN Serap,SALMAN Andaç,borlu murat,senturk nilgun,KARAKAŞ Ayşe AKMAN,Serdaroğlu Server Atopic dermatitis diagnosis and treatment consensus report. , 2022, ss.86 - 121. 10.4274/turkderm.galenos.2022.73368
AMA	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S Atopic dermatitis diagnosis and treatment consensus report. . 2022; 86 - 121. 10.4274/turkderm.galenos.2022.73368
Vancouver	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S Atopic dermatitis diagnosis and treatment consensus report. . 2022; 86 - 121. 10.4274/turkderm.galenos.2022.73368
IEEE	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S "Atopic dermatitis diagnosis and treatment consensus report." , ss.86 - 121, 2022. 10.4274/turkderm.galenos.2022.73368
ISNAD	atakan, nilgün vd. "Atopic dermatitis diagnosis and treatment consensus report". (2022), 86-121. https://doi.org/10.4274/turkderm.galenos.2022.73368

APA	atakan n, Yalcin B, ÖZKAYA E, Su O, ÖZTÜRKCAN S, SALMAN A, borlu m, senturk n, KARAKAŞ A, Serdaroğlu S (2022). Atopic dermatitis diagnosis and treatment consensus report. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(2), 86 - 121. 10.4274/turkderm.galenos.2022.73368
Chicago	atakan nilgün,Yalcin Basak,ÖZKAYA Esen,Su Ozlem,ÖZTÜRKCAN Serap,SALMAN Andaç,borlu murat,senturk nilgun,KARAKAŞ Ayşe AKMAN,Serdaroğlu Server Atopic dermatitis diagnosis and treatment consensus report. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.2 (2022): 86 - 121. 10.4274/turkderm.galenos.2022.73368
MLA	atakan nilgün,Yalcin Basak,ÖZKAYA Esen,Su Ozlem,ÖZTÜRKCAN Serap,SALMAN Andaç,borlu murat,senturk nilgun,KARAKAŞ Ayşe AKMAN,Serdaroğlu Server Atopic dermatitis diagnosis and treatment consensus report. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.2, 2022, ss.86 - 121. 10.4274/turkderm.galenos.2022.73368
AMA	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S Atopic dermatitis diagnosis and treatment consensus report. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(2): 86 - 121. 10.4274/turkderm.galenos.2022.73368
Vancouver	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S Atopic dermatitis diagnosis and treatment consensus report. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(2): 86 - 121. 10.4274/turkderm.galenos.2022.73368
IEEE	atakan n,Yalcin B,ÖZKAYA E,Su O,ÖZTÜRKCAN S,SALMAN A,borlu m,senturk n,KARAKAŞ A,Serdaroğlu S "Atopic dermatitis diagnosis and treatment consensus report." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.86 - 121, 2022. 10.4274/turkderm.galenos.2022.73368
ISNAD	atakan, nilgün vd. "Atopic dermatitis diagnosis and treatment consensus report". Türkderm Türk deri hastalıkları ve frengi arşivi 56/2 (2022), 86-121. https://doi.org/10.4274/turkderm.galenos.2022.73368